title: [Effects of endothelin antagonists on isolated perfused murine livers in the early phase of warm ischemia-reperfusion injury under propofol anesthesia].
abstract: We investigated the effects of selective and non-selective endothelin (ET) antagonists on warm ischemia-reperfusion injury of the early phase in the murine liver under propofol anesthesia. We examined portal pressures, O2 consumptions and liver enzymes to estimate injuries using perfused isolated murine liver model. Experiment 1: we compared the perfusate only group, the soy oil (as vehicle) group, and the propofol group without ischemic loading to determine whether propofol and its vehicles themselves have any effect. Experiment 2: we determined the effects of ET antagonists on reperfusion injury after warm ischemia of 40 minute's cutoff of perfusate under propofol anesthesia and compared five groups up to 90 min after reperfusion; the propofol only group (control; 4 mg.l-1), the BQ-485 group (20 microM), the BQ-788 group (50 microM), the bosentan group (40 microM), and the BQ-485 + BQ-788 group. The soy oil group showed significantly more liver damage, and the propofol group showed no damage. In addition, propofol did not alter the effect of ET antagonists on reperfusion injury. Clinical dose of propofol did not seem to alter the effects of ET antagonists on the murine liver in the early phase of ischemia-reperfusion injury.
authors.affiliation: Department of Anesthesiology, National Defense Medical College, Tokorozawa.
authors.forename: K
authors.initials: K
authors.lastname: Tanaka
authors.forename: F
authors.initials: F
authors.lastname: Karasawa
authors.forename: T
authors.initials: T
authors.lastname: Sato
mesh_terms: D000771:Anesthesia, Intravenous; D018686:Anesthetics, Intravenous; D000818:Animals; D001381:Azepines / Q000627:therapeutic use; D000077300:Bosentan; D004195:Disease Models, Animal; D016232:Endothelins / Q000037:antagonists & inhibitors*; D016166:Free Radical Scavengers; D066298:In Vitro Techniques; D008099:Liver / Q000098:blood supply*; D008297:Male; D009842:Oligopeptides / Q000009:adverse effects / Q000627:therapeutic use; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use; D015742:Propofol; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000517:prevention & control*; D013449:Sulfonamides / Q000627:therapeutic use
chemical_list: D018686:Anesthetics, Intravenous; D001381:Azepines; D016232:Endothelins; D016166:Free Radical Scavengers; D009842:Oligopeptides; D010880:Piperidines; D013449:Sulfonamides; C083116:BQ 485; C086539:BQ 788; D000077300:Bosentan; D015742:Propofol